Recent Quotes (30 days)

You have no recent quotes
chg | %

Pivotal Therapeutics Inc  

(Public, CNSX:PVO)   Watch this stock  
Find more results for PVO
0.0000
-0.0250 (-100.00%)
Real-time:  
CNSX real-time data - Disclaimer
Currency in CAD
Range     -
52 week 0.00 - 0.05
Open     -
Vol / Avg. 0.00/2,000.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -0.04
Shares 96.57M
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -1005.23% -1755.14%
Operating margin -550.16% -1780.33%
EBITD margin - -1746.57%
Return on average assets -298.73% -256.34%
Return on average equity - -
CDP Score - -

Address

81 Zenway Blvd Unit 10
WOODBRIDGE, ON L4H 0S5
Canada
+1-905-8569797 (Phone)
+1-905-8562177 (Fax)

Website links

Description

Pivotal Therapeutics Inc. is a specialty pharmaceutical company. The Company's product portfolio consists of three lines: VASCAZEN, OMAZEN and Benefishial. It specializes in cardiovascular science, focused on cardiovascular disease and overall health. Its lead prescription only medical food product, VASCAZEN, is used for the clinical dietary management of cardiovascular disease in patients with documented coronary heart disease and deficient in blood Omega-3 fatty acids, Eicosapentaenoic Acid EPA) and Docosahexanenoic Acid (DHA) levels. VASCAZEN is a pharmaceutical formulation of EPA:DHA and provides the cornerstone upon, which a family of combination products, having efficacy across a spectrum of cardiac indications, will be developed, and for, which the Company is developing a Property portfolio. OMAZEN is commercialized in Canada for the maintenance of good health through Omega-3 fatty acid levels. Benefishial targets consumer market place and consists of six various products.

Officers and directors

John S. Gebhardt Independent Chairman of the Board
Age: 67
Rachelle MacSweeney President, interim Chief Executive Officer, Chief Operating Officer, Director
George Jackowski Ph.D. Chief Scientific Officer, Director
Giuseppe Simeone Independent Director